Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other brokerages also recently commented on NBRV. Zacks Investment Research downgraded shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th. Northland Securities reduced their target price on shares of Nabriva Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 30th.

Shares of Nabriva Therapeutics stock opened at $0.37 on Wednesday. The firm has a market capitalization of $222.73 million, a PE ratio of -0.29 and a beta of 1.55. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.59 and a quick ratio of 2.94. The company’s fifty day moving average price is $0.44 and its two-hundred day moving average price is $0.68. Nabriva Therapeutics has a 52-week low of $0.35 and a 52-week high of $2.32.

Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05). The business had revenue of $9.26 million during the quarter, compared to the consensus estimate of $10.30 million. Nabriva Therapeutics had a negative net margin of 171.14% and a negative return on equity of 82.13%. During the same period last year, the firm earned ($1.11) EPS. Analysts predict that Nabriva Therapeutics will post -0.67 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Nabriva Therapeutics during the 4th quarter worth about $125,000. GSA Capital Partners LLP acquired a new position in Nabriva Therapeutics during the 4th quarter worth about $214,000. Renaissance Technologies LLC lifted its position in Nabriva Therapeutics by 116.3% during the 4th quarter. Renaissance Technologies LLC now owns 471,300 shares of the biotechnology company’s stock worth $282,000 after buying an additional 253,415 shares in the last quarter. Two Sigma Securities LLC acquired a new position in Nabriva Therapeutics during the 3rd quarter worth about $48,000. Finally, Millennium Management LLC lifted its position in Nabriva Therapeutics by 218.5% during the 3rd quarter. Millennium Management LLC now owns 99,151 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 68,018 shares during the period. Institutional investors and hedge funds own 1.36% of the company’s stock.

Nabriva Therapeutics Company Profile (Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Featured Articles